Biosynex SA (FRA:0DL)

Market Cap	9.30M
Revenue (ttm)	97.95M
Net Income (ttm)	-70.99M
Shares Out	n/a
EPS (ttm)	-4.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	5
Open	0.4830
Previous Close	0.4860
Day's Range	0.4830 - 0.4830
52-Week Range	0.4830 - 2.7100
Beta	n/a
RSI	32.99
Earnings Date	Apr 30, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products. The company was founded in 1993 and is based in Illkirch-Graf...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1993
• Employees: 476
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0DL

Financial Performance

In 2024, Biosynex's revenue was 101.17 million, an increase of 8.81% compared to the previous year's 92.98 million. Losses were -43.33 million, 17.3% more than in 2023.